![Louis Brenner](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Louis Brenner
Corporate Officer/Principal chez
Harvard University
Profil
Louis Brenner is currently a Lecturer at Harvard University.
Formerly, Dr. Brenner was President, Chief Executive Officer & Director at Hopewell Therapeutics, Inc. from 2022 to 2024, and held the same titles at Allena Pharmaceuticals, Inc. from 2019 to 2022.
Other former roles include Chief Medical Officer & Senior Vice President at Idera Pharmaceuticals, Inc. (2014-2015), Chief Medical Officer & Senior Vice President at Radius Health, Inc. (2012-2014), Senior Vice President at AMAG Pharmaceuticals, Inc. (2006-2010), Senior Director-Business Development-Renal Unit at Genzyme Corp.
(2002-2006), and Director positions at PLC Medical Systems, Inc. and Goldfinch Bio, Inc. Education includes a doctorate from Duke University (1996), an undergraduate degree from Yale University (1992), and an MBA from Harvard Business School (2002).
Postes actifs de Louis Brenner
| Sociétés | Poste | Début |
|---|---|---|
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Anciens postes connus de Louis Brenner
| Sociétés | Poste | Fin |
|---|---|---|
Hopewell Therapeutics, Inc.
 Hopewell Therapeutics, Inc. BiotechnologyHealth Technology Develops novel synthetic lipid based nanoparticles for nucleic acid delivery for gene therapy & gene editing | Directeur Général | 01/06/2024 |
| ALLENA PHARMACEUTICALS, INC. | Directeur Général | 02/09/2022 |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Directeur Technique/Scientifique/R&D | 01/04/2015 |
| RADIUS HEALTH, INC. | Directeur Technique/Scientifique/R&D | 02/01/2014 |
| AMAG PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/12/2010 |
Formation de Louis Brenner
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
92
Relations au 1er degré
12
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 12 |
|---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Health Technology |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops and commercializes bone health and related therapeutics | Health Technology |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AMAG Pharmaceuticals, Inc.
 AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
PLC Medical Systems, Inc.
 PLC Medical Systems, Inc. Medical SpecialtiesHealth Technology Manufactures and wholesales medical devices | Health Technology |
Allena Pharmaceuticals, Inc.
 Allena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and retails drugs through online | Health Technology |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Goldfinch Bio, Inc.
 Goldfinch Bio, Inc. Pharmaceuticals: MajorHealth Technology Develop medicines and therapies for patients with kidney disease | Health Technology |
Hopewell Therapeutics, Inc.
Hopewell Therapeutics, Inc. BiotechnologyHealth Technology Develops novel synthetic lipid based nanoparticles for nucleic acid delivery for gene therapy & gene editing | Health Technology |
